Shares of Merit Medical Systems (NASDAQ: MMSI) surged 5.67% in after-hours trading on Thursday, following the release of the company's impressive third-quarter 2025 financial results that beat analysts' expectations and prompted an upward revision of full-year guidance.

The medical device manufacturer reported Q3 revenue of $384.2 million, representing a 13% year-over-year increase and surpassing the consensus estimate of $371.9 million. The company's adjusted earnings per share (EPS) came in at $0.92, significantly above the expected $0.83. Merit Medical's strong performance was largely driven by its Cardiac Intervention segment, which saw a substantial 29.3% revenue growth compared to the same period last year.

In light of these robust results, Merit Medical Systems has raised its full-year 2025 guidance. The company now expects annual revenue to be between $1.502 billion and $1.515 billion, up from previous estimates. Additionally, the non-GAAP EPS guidance has been updated to a range of $3.66 to $3.79. Martha G. Aronson, Merit's President and CEO, attributed the strong performance to effective execution and stable growth across the company's product lines. The raised outlook and improved profitability metrics have clearly resonated with investors, as reflected in the stock's after-hours rally.